Johan Isaksson

Johan Isaksson

Auto-generated profile, based on publicly available information

Johan Isaksson

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Centre for Research and Development, Uppsala University, Uppsala, Region Gävleborg, Sweden

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2018 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
LFLinnéa La Fleur
Linnéa La Fleur
VBVanessa F. Boura
Vanessa F. Boura
AAAndrey Alexeyenko
Andrey Alexeyenko
ABAnders Berglund
Anders Berglund
VPVictor Pontén
Victor Pontén
JBJohan Botling
Johan Botling

24 February 2023 in European Journal of Cancer
Verified
Journal Article
Open access
MBMax Backman
Max Backman
CSCarina Strell
Carina Strell
ALAmanda Lindberg
Amanda Lindberg
JMJohanna S.M. Mattsson
Johanna S.M. Mattsson
HEHedvig Elfving
Hedvig Elfving
PMPatrick Micke
Patrick Micke
Immune cells in the tumour microenvironment are associated with prognosis and response to therapy. We aimed to comprehensively characterise the spatial immune phenotypes in the mutational and clinicopathological background of non-small cell lung cancer (NSCLC). We established a multiplexed fluorescence imaging pipeline to spatially quantify 13 immune cell subsets in 359 NSCLC cases: CD4 effector cells (CD4-Eff), CD4 regulatory cells (CD4-Treg), CD8 effector cells (CD8-Eff), CD8 regulatory cells (CD8-Treg), B-cells, natural killer cells, natural killer T-cells, M1 macrophages (M1), CD163+ myeloid cells (CD163), M2 macrophages (M2), immature dendritic cells (iDCs), mature dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs). CD4-Eff cells, CD8-Eff cells and M1 macrophages were the most abundant immune cells invading the tumour cell compartment and indicated a patient group with a favourable prognosis in the cluster analysis. Likewise, single densities of lymphocytic subsets (CD4-Eff, CD4-Treg, CD8-Treg, B-cells and pDCs) were independently associated with longer survival. However, when these immune cells were located close to CD8-Treg cells, the favourable impact was attenuated. In the multivariable Cox regression model, including cell densities and distances, the densities of M1 and CD163 cells and distances between cells (CD8-Treg-B-cells, CD8-Eff-cancer cells and B-cells-CD4-Treg) demonstrated positive prognostic impact, whereas short M2-M1 distances were prognostically unfavourable. We present a unique spatial profile of the in situ immune cell landscape in NSCLC as a publicly available data set. Cell densities and cell distances contribute independently to prognostic information on clinical outcomes, suggesting that spatial information is crucial for diagnostic use.

11 May 2023 in Clinical Lung Cancer
Verified
Journal Article
Open access
JIJohan Isaksson
Johan Isaksson
ABAnders Berglund
Anders Berglund
KLKarly Louie
Karly Louie
LWLinda Willén
Linda Willén
AHArash Hamidian
Arash Hamidian
JBJohan Botling
Johan Botling
Real-world data on demographics related to KRAS mutation subtypes are crucial as targeted drugs against the p.G12C variant have been approved. We identified 6183 NSCLC patients with reported NGS-based KRAS status in the Swedish national lung cancer registry between 2016 and 2019. Following exclusion of other targetable drivers, three cohorts were studied: KRAS-G12C (n = 848), KRAS-other (n = 1161), and driver negative KRAS-wild-type (wt) (n = 3349). The prevalence of KRAS mutations and the p.G12C variant respectively was 38%/16% in adenocarcinoma, 28%/13% in NSCLC-NOS and 6%/2% in squamous cell carcinoma. Women were enriched in the KRAS-G12C (65%) and KRAS-other (59%) cohorts versus KRAS-wt (48%). A high proportion of KRAS-G12C patients in stage IV (28%) presented with CNS metastasis (vs. KRAS-other [19%] and KRAS-wt [18%]). No difference in survival between the mutation cohorts was seen in stage I-IIIA. In stage IV, median overall survival (mOS) from date of diagnosis was shorter for KRAS-G12C and KRAS-other (5.8 months/5.2 months) vs. KRAS wt (6.4 months). Women had better outcome in the stage IV cohorts, except in KRAS-G12C subgroup where mOS was similar between men and women. Notably, CNS metastasis did not impact survival in stage IV KRAS-G12C, but was associated with poorer survival, as expected, in KRAS-other and KRAS-wt. The KRAS p.G12C variant is a prevalent targetable driver in Sweden and significantly associated with female sex and presence of CNS metastasis. We show novel survival effects linked to KRAS p.G12C mutations in these subgroups with implications for clinical practice.

14 November 2021 in Acta Oncologica
Verified
Journal Article
Open access
LWLinda Willén
Linda Willén
ABAnders Berglund
Anders Berglund
SBStefan Bergström
Stefan Bergström
JIJohan Isaksson
Johan Isaksson
MBMichael Bergqvist
Michael Bergqvist
MLMats Lambe
Mats Lambe
Results from studies addressing age-related patterns of cancer care have found evidence of unjustified differences in management between younger and older patients.We examined associations between ...

3 March 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
APAndreas Palm
Andreas Palm
JTJ Theorell-Haglöw
J Theorell-Haglöw
JIJohan Isakson
Johan Isakson
MLMirjam Ljunggren
Mirjam Ljunggren
JSJosefin Sundh
Josefin Sundh
LGLudger Grote
Ludger Grote
Objectives: Nocturnal hypoxia in obstructive sleep apnoea (OSA) is a potential risk factor for cancer. We aimed to investigate the association between OSA measures and cancer prevalence in a large national patient cohort. Design: Cross-sectional study. Settings: 44 sleep centres in Sweden. Participants: 62 811 patients from the Swedish registry for positive airway pressure (PAP) treatment in OSA, linked to the national cancer registry and national socioeconomic data (the course of DIsease in patients reported to Swedish CPAP, Oxygen and VEntilator RegistrY cohort). Outcome measures: After propensity score matching for relevant confounders (anthropometric data, comorbidities, socioeconomic status, smoking prevalence), sleep apnoea severity, measured as Apnoea-Hypopnoea Index (AHI) or Oxygen Desaturation Index (ODI), were compared between those with and without cancer diagnosis up to 5 years prior to PAP initiation. Subgroup analysis for cancer subtype was performed. Results: OSA patients with cancer (n=2093) (29.8% females, age 65.3 (SD 10.1) years, body mass index 30 (IQR 27–34) kg/m 2 ) had higher median AHI (n/hour) (32 (IQR 20–50) vs 30 (IQR 19–45), n/hour, p=0.002) and median ODI (n/hour) (28 (IQR 17–46) vs 26 (IQR 16–41), p<0.001) when compared with matched OSA patients without cancer. In subgroup analysis, ODI was significantly higher in OSA patients with lung cancer (N=57; 38 (21–61) vs 27 (16-43), p=0.012)), prostate cancer (N=617; 28 (17–46) vs 24, (16–39)p=0.005) and malignant melanoma (N=170; 32 (17–46) vs 25 (14–41),p=0.015). Conclusions: OSA mediated intermittent hypoxia was independently associated with cancer prevalence in this large, national cohort. Future longitudinal studies are warranted to study the potential protective influence of OSA treatment on cancer incidence.

15 December 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LWLinda Willén
Linda Willén
ABAnders Berglund
Anders Berglund
SBStefan Bergström
Stefan Bergström
JIJohan Isaksson
Johan Isaksson
MBMichael Bergqvist
Michael Bergqvist
MLMats Lambe
Mats Lambe
Objectives: While studies have found lower cancer risks and better cancer survival in immigrant populations, it is debated whether cancer care is offered on equal terms to all residents regardless of background. Our aim was to study patterns of care and outcomes in immigrants in a country with a tax-financed universal health care system. Material and methods: We used a population-based database to compare clinical presentation, management and mortality between Swedish-born and immigrant patients with non-small cell lung cancer (NSCLC). Analyses were adjusted for potential confounders. Results: We identified 40,075 patients diagnosed with NSCLC of which 84% were born in Sweden, 7% in Nordic and 9% in Non-Nordic countries. Non-Nordic immigrants were to a higher extent male, smokers, younger at diagnosis, had a better performance status and a higher educational level. No differences were seen regarding comorbidity burden or stage at diagnosis. Non-Nordic immigrants more often underwent positron emission tomography (PET) (aHR 1.32; 95% CI 1.19–1.45) and were more often discussed in a multidisciplinary team setting (aHR 1.30; 95% CI 1.17–1.44). There were no differences in treatment modalities following adjustment for age, with the exception of concurrent chemoradiotherapy in stage IIIA disease which was more common in Non-Nordic immigrants (aOR 1.34; 95% CI 1.03–1.74). Both overall and cause specific survival in non-metastatic disease were higher among Non-Nordic immigrants. Overall mortality in stage I-II: HR 0.81; 95% CI 0.73–0.90 and stage IIIA: HR 0.75; 95% CI 0.65–0.86. Following full adjustments, cause-specific mortality in stage I-II was aHR 0.86, 95% CI 0.75–0.98. Conclusion: Taken together, only minor differences in management and outcomes were observed between Swedish-born and immigrant patients. We conclude that lung cancer care is offered on equal terms. If anything, outcomes were better in Non-Nordic immigrants with early stage NSCLC.